3rd Quarter - Report

WALGREEN COMPANY for WALGREEN COMPANY

Firm
Client
Income
—
Expenses
$470,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

H.R. 592 / S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. H.R. 3528 / S. 2460 and H.R. 6 - These bills would amend title XVIII of the Social Security Act to require e-prescribing under Part D of the Medicare program of prescription drugs that are controlled substances. Issues related to American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; no legislation.

LobbyistCovered position, as disclosed
KATHARINE TROLLER BOND —
ALETHIA JACKSON —
EDWARD KALETA —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 109 (115th), H.R. 592 (115th), H.R. 6 (115th), S. 2460 (115th), H.R. 3528 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.